Enzyme Sample Clauses

Enzyme. The enzyme is [**]. The Partner Territory consists of the 27 members of the European Union as of the date of this Agreement, specifically Austria, Belgium, Bulgaria, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, The Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden and the UK, and Croatia, Albania, Armenia, Azerbaijan, Belarus, Bosnia & Xxxxxxxxxxx, Xxxxxxx, Xxxxxxxxxx, Xxxxxxx Xxxxxxxx, Xxxxxxxxx, Xxxxxxx, Xxxxxx & Montenegro, Tajikistan, Uzbekistan, Turkey, Iceland, Switzerland and Norway. [**] [**] [**] BioSpecifics Technologies Corp. 00 Xxxxxx Xxxxxx Lynbrook, New York 11563 Attention: Xxxxxx Xxxxxx, President Dear Xxx: In connection with the Amended and Restated Development and License Agreement (the “ License Agreement”) between us, dated as of December , 2008, we wish to confirm to you as follows:

Enzyme. This retention of records may be extended if there is a legal proceeding pending (i.e., court action, or US interference or opposition involving the Intellectual Property) where those records are reasonably required and a written request with the reason is provided to the Party. Nothing herein shall require, or be construed to require, that DIVERSA disclose to DOW any DIVERSA Know-How, except to the extent necessary for the filing of patent applications [*****]. DOW shall not be required to disclose to DIVERSA any DOW Know-How or any DOW [*****] on any Research [*****], Research [*****] or [*****] Enzyme, except for the reasonable information required by the RMC.

Enzyme. During the Term, within [***] after the end of each Calendar Year, Merck shall deliver to Codexis a written notice identifying each (a) Fee Bearing Therapeutic Product and the Merck Developed API contained within each Fee Bearing Therapeutic Product and (b) Therapeutic Product (and the Merck Developed API contained within each such Therapeutic Product) that (i) is in active development by Merck, its Affiliates or a permitted licensee or assign and (ii) is being evaluated or has been evaluated in a Phase III Clinical Trial. During the Term, Codexis may from time to time request from Merck to confirm to Codexis whether a specific Therapeutic that (i) is in active development by Merck, its Affiliates or a permitted licensee or assign and (ii) is being evaluated or has been evaluated in a Phase III Clinical Trial is manufactured using an Enzyme, and Merck will respond in writing within a reasonable time to such written request from Codexis.

Enzyme. Schedule 1.2.1 Enzyme

Enzyme. 1.1.1 Purity *** > 92 % 1.1.2 Double-stranded Endonuclease contamination Incubation of *** at 37 0C No change in band pattern upon agarose gel electrophoresis. 1.1.3 Single-stranded endonucleases contamination Incubation of *** at 37 0C No change in band pattern upon agarose gel electrophoresis. 1.1.4 Protein concentration Comparison to BSA standard curve at A595. *** 1.2.1 Base composition HPLC analysis *** ***

Enzyme. 1.1.1 Purity *** *** 1.1.2 Double-stranded Endonuclease contamination Incubation of *** *** 1.1.3 Single-stranded endonucleases contamination Incubation of *** *** 1.1.4 Protein concentration Comparison to *** *** 1.2.1 Base composition *** ***

Enzyme reactions in ILs and DES (factors affecting the enzyme activity in ILs and DES)

Enzyme. Next * projected sales of Ceredase(R) and Cerezyme(R) is based upon Genzyme's * amount for Nova Factor with Nova Factor's agreement but that in no event will be less than the * unless agreed to by Genzyme.

Enzyme. The enzyme is collagenase obtained by fermentation of Clostridium histolyticum, purified by chromatography, lyophilized and substantially free from other proteinases.

Enzyme. 1.81 “Merck Exclusive Field” means the research, development, and manufacture of Covered Enzymes and Enzymes for use in the animal and/or human healthcare field solely by Merck and its Affiliates, or on behalf of Merck and its Affiliates in accordance with Section 3.2, in the chemical synthesis of Therapeutic Products owned or Controlled by Merck (including, for clarity, the chemical synthesis of Merck Developed APIs for formulation into any Therapeutic Controlled by Merck), but excluding, in any event, the discovery of any Therapeutic Enzyme, Diagnostic, or Vaccine. 1.82 “Merck Initial Enzyme(s)” means any enzyme (which for clarity is not an “Enzyme”) that is provided by Merck and which is designated as an Initial Enzyme pursuant to a Technology Transfer Project excluding, for clarity, Enzymes derived from a Codexis Enzyme or a Codexis Library. 1.83 “Merck Non-Exclusive Field” means the research, development, and manufacture of Covered Enzymes and Enzymes for use solely by Merck and its Affiliates, or on behalf of Merck and its Affiliates in accordance with Section 3.2, for Internal Research Purposes, but excluding, in any event, the discovery of any Therapeutic Enzyme, Diagnostic, or Vaccine, or any sale, lease, license, transfer or use of such Covered Enzymes or Enzymes as a standalone product or a component of a product. 1.84 “Merck Project Library” means any collection, set or sub-set of Enzymes and/or expression vectors containing genes that encode for Enzymes derived from a Technology Transfer Project. 1.85 “Option Improvements” means all Improvements relating to the Platform Technology, including, without limitation, Codexis Core Technology Improvements (including any and all Improvements to the Codexis Methods, the Initial Technology Transfer Inventory and the Codexis [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. - 10 – Execution Version Software), Improvements to the Codexis Materials and/or the Codexis Documentation, which have come to be Controlled by Codexis during the applicable Option Year. 1.86 “Option Year” means each of the [***] twelve (12)-month periods commencing with the day immediately following the TT Term Expiration Date and thereafter commencing with each anniversary thereof. For clarity, the [***]. 1.87 “Patent(s)” means (a) patents and patent applications anywhere in the ...